调强放疗再照射治疗局部复发T3至T4期鼻咽癌
本研究回顾性分析2005至2013年连续收治的38例rT3至rT4期鼻咽癌患者,评估调强放疗再照射的疗效与毒性。3年总生存率47.2%、无进展生存率17.5%、局部控制率44.3%;73.7%患者出现至少1项3级晚期毒性,3例死于大量鼻出血。作者认为充分的肿瘤剂量覆盖对治疗rT3至rT4期鼻咽癌很重要。
要点
- 38例rT3至rT4期鼻咽癌再照射,3年总生存率47.2%、无进展生存率17.5%、局部控制率44.3%
- GTV D95、GTV D50与年龄是总生存和无进展生存的重要预后因素,仅GTV D95是局部控制的重要决定因素
- 73.7%患者出现至少1项3级晚期毒性,3例死于大量鼻出血;颞叶坏死(TLN)在总生物等效剂量较高时更早发生
核心结论
- 充分的肿瘤剂量覆盖对治疗rT3至rT4期鼻咽癌很重要。
- 尽管晚期并发症常见,治疗相关死亡均属血管性。
- 再照射时神经系统结构的剂量约束应依据最新晚期毒性信息修订。
研究设计与样本
- 回顾性分析2005至2013年间连续治疗的38例rT3至rT4期鼻咽癌患者,评估调强放疗再照射的疗效与毒性。
主要发现
- 3年总生存率47.2%、无进展生存率17.5%、局部控制率44.3%。
- GTV D95、GTV D50和年龄均为总生存与无进展生存的重要预后因素,但仅GTV D95是局部控制的重要决定因素。
- 73.7%患者出现至少1项3级晚期毒性,3例死于大量鼻出血。
- 总生物等效剂量较高时颞叶坏死(TLN)发生更早。
临床怎么用
- 作者认为充分的肿瘤剂量覆盖对治疗rT3至rT4期鼻咽癌很重要。
- 作者提出再照射时神经系统结构的剂量约束应依据最新晚期毒性信息修订。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to assess the efficacy and toxicities of reirradiation using intensity-modulated radiotherapy (IMRT) in patients with locally advanced recurrent nasopharyngeal carcinoma (NPC). METHODS: Thirty-eight patients with consecutive rT3 to rT4 NPC treated between 2005 and 2013 were retrospectively analyzed. RESULTS: The 3-year overall survival (OS), progression-free survival (PFS), and local control rate were 47.2%, 17.5%, and 44.3%, respectively. Gross target volume (GTV) D95 , GTV D50 , and age were all important prognostic factors for OS and PFS, but only GTV D95 was an important determinant for local control. A total of 73.7% patients experienced ≥1 grade 3 late toxicities and 3 patients died of massive epistaxis. Temporal lobe necrosis (TLN) developed sooner with a higher total biological equivalent dose. CONCLUSION: Adequate tumor dose coverage was important for treating rT3 to rT4 NPC. Although late complications were common, treatment-related mortality was solely vascular in nature. Dose constraints of neurologic structures for reirradiation should be revised with the latest information on late toxicities. © 2016 Wiley Periodicals, Inc. Head Neck 39: 533-540, 2017.
引用
- Chan OS, Sze HC, Lee MC, et al. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. Head Neck. 2016. PMID: 27898191. doi:10.1002/hed.24645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。